Biocardia announces activation of cardiamp heart failure ii phase 3 pivotal study recently approved by fda

Sunnyvale, calif., feb. 08, 2024 (globe newswire) -- biocardia, inc. (“biocardia” or the “company”) (nasdaq: bcda), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, is targeting heart failure and chronic myocardial ischemia as potential indications for its biotherapeutic candidates: autologous cardiamp® cell therapy and allogeneic cardiallo™ cell therapy.
BCDA Ratings Summary
BCDA Quant Ranking